Episode 245: ASCO 2023 - CONTACT-03 and Cabozantinib +/- Atezolizumab in RCC

By The Uromigos - Last Updated: August 1, 2023

We’re joined by Toni Choueiri, MD, at ASCO 2023 to discuss the CONTACT-03 trial. The phase 3 study investigated the efficacy of atezolizumab plus cabozantinib versus cabozantinib monotherapy after progression on or after ICI treatment in patients with advanced or metastatic renal cell carcinoma.
Dr. Choueiri is the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute.

Post Tags:Uromigos-ASCOUromigos-ASCO 2023-Kidney CancerUromigos-Kidney Cancer